These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11377572)

  • 1. The effect of Neoral on plasma cholesterol concentration in renal transplant recipients.
    Konstadinidou I; Boletis JN; Chelioti H; Avdikou K; Theodoropoulou H; Gounari P; Kostakis A; Stathakis CP
    Transplant Proc; 2001 May; 33(3):2393-4. PubMed ID: 11377572
    [No Abstract]   [Full Text] [Related]  

  • 2. Conversion from Sandimmune to Neoral in renal transplant recipients: two-year experience.
    Wilczek HE; Akesson P; Warholm C
    Transplant Proc; 1998 Aug; 30(5):1753-5. PubMed ID: 9723267
    [No Abstract]   [Full Text] [Related]  

  • 3. Converting renal transplant patients maintained on Sandimmune to a new microemulsion formulation, Sandimmune Neoral.
    Chu SH; Pang ST; Chiang YJ; Chuang CK; Chen HW; Chen CS; Chou CC; Huang CC
    Transplant Proc; 1998 Nov; 30(7):3521-3. PubMed ID: 9838543
    [No Abstract]   [Full Text] [Related]  

  • 4. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a Neoral-equivalent cyclosporine formulation, using a dose-adjusted method.
    First MR; Weiskittel P; Shah M; Peddi VR; Canafax D; Schroeder TJ
    Transplant Proc; 1998 Dec; 30(8):3955-7. PubMed ID: 9865260
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and efficacy of conversion from once daily Sandimmun to twice daily Neoral cyclosporine in renal allograft recipients.
    Vathsala A; Lee WT; Lu YM; Woo KT
    Transplant Proc; 1998 Aug; 30(5):1746-8. PubMed ID: 9723264
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term experience with Sandimmun Neoral: results in de novo and stable renal transplant patients after 24-month treatment. The German Neoral Study Group.
    Korn A; Färber L; Maibücher A; Buchholz B; Offermann G
    Transplant Proc; 1997 Nov; 29(7):2945-7. PubMed ID: 9365623
    [No Abstract]   [Full Text] [Related]  

  • 7. Case reports on conversion to Neoral therapy in renal transplant patients.
    Curtis JJ
    Transplant Proc; 1996 Aug; 28(4):2221-2; discussion 2218. PubMed ID: 8769205
    [No Abstract]   [Full Text] [Related]  

  • 8. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
    Løkkegaard H; Asmundsson P; Clausen P; Dieperink H; Hansen JM; Heaf J; Jensen SB; Kornerup HJ; Madsen S; Pedersen EB; Poulsen JV; Rasmussen K
    Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
    [No Abstract]   [Full Text] [Related]  

  • 9. Conversion to cyclosporine microemulsion (Neoral) in stable renal transplant patients: results from a single center.
    Cossu M; Satta R; Branca GF; Pala PG; Serra G; Satta RP; Sorba G
    Transplant Proc; 1998 Aug; 30(5):1762-3. PubMed ID: 9723271
    [No Abstract]   [Full Text] [Related]  

  • 10. Case study: de novo application of Neoral in renal transplantation.
    Kahan BD
    Transplant Proc; 1996 Aug; 28(4):2189-91; discussion 2192, 2195. PubMed ID: 8769196
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclosporine pharmacokinetic profiles in stable renal allograft recipients converting from Sandimmun to Neoral.
    Vathsala A; Lee WT; Jacob E; Woo KT
    Transplant Proc; 1996 Jun; 28(3):1324-6. PubMed ID: 8658678
    [No Abstract]   [Full Text] [Related]  

  • 12. Cyclosporin Neoral and long-term survival of renal grafts.
    Shaheen FA; Sheikh IA; al-Khader A
    Transplant Proc; 1998 Nov; 30(7):3549. PubMed ID: 9838553
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. German Neoral Study Group.
    Offermann G; Korn A
    Transplant Proc; 1996 Aug; 28(4):2204-6. PubMed ID: 8769201
    [No Abstract]   [Full Text] [Related]  

  • 14. Conversion from Sandimmune to Neoral and induction therapy with Neoral in pediatric renal transplant recipients.
    Hoyer PF; Boekenkamp A; Vester U; Offner G; Brodehl J
    Transplant Proc; 1996 Aug; 28(4):2259-61. PubMed ID: 8769218
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of efficacy, safety, and tolerability of Neoral vs Sandimmun in de novo renal transplant patients over 24 months' treatment.
    Abendroth D; Buchholz B; Land W; May G; Wiesel M; Färber L; Korn A; Maibücher A
    Transplant Proc; 1997; 29(1-2):275-6. PubMed ID: 9122993
    [No Abstract]   [Full Text] [Related]  

  • 16. Cyclosporine does not influence serum cholesterol in kidney transplant recipients.
    Matzkies FK; Keuthage W; Kobelt V; Hillebrand U; Gerhardt U; Suwelack B; Hohage H
    Transplant Proc; 2002 Aug; 34(5):1795-6. PubMed ID: 12176580
    [No Abstract]   [Full Text] [Related]  

  • 17. Neoral versus Sandimmune in kidney transplantation.
    Tisone G; Orlando G; Mercadante E; Vennarecci G; Pisani F; Buonomo O; Negrini S; Casciani CU
    Transplant Proc; 1998 Aug; 30(5):1749-50. PubMed ID: 9723265
    [No Abstract]   [Full Text] [Related]  

  • 18. Conversion from Sandimmune to Neoral in stable renal transplant recipients. Sandoz Study Group OLN-353.
    Pescovitz MD
    Transplant Proc; 1996 Aug; 28(4):2196-8. PubMed ID: 8769198
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclosporine Neoral in renal transplant recipients: impact on hepatic dysfunction.
    Bakr MA; Refaie A; Mekresh M; Ihab MH; Sobh M; Ghoneim MA
    Transplant Proc; 1997 Nov; 29(7):2939-40. PubMed ID: 9365621
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of conversion from Sandimmune to Neoral on glomerular filtration rate in stable renal transplant recipients.
    Steinmuller D; Dougherty J; Coutee J; Surek D; Swies G; Lewis R
    Transplant Proc; 1997; 29(1-2):298-9. PubMed ID: 9123005
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.